Tous Actualités
Suivre
Abonner Debiopharm International SA

Debiopharm International SA

Debiopharm Diagnostics Leads Investment Round in GenePOC With Emerillon Capital

Switzerland (ots/PRNewswire)

GenePOC is a Canadian company which has developed a rapid, innovative, low cost MDx platform for the detection of infectious diseases

Debiopharm Diagnostics [https://www.debiopharm.com/about-us/debiopharm-diagnostics-s-a.html], part of Debiopharm Group [https://www.debiopharm.com/about-us/debiopharm-group.html](TM), is proud to be the lead investor in GenePOC, which is developing a highly innovative, low cost and quick MDx (Molecular Diagnostics) platform. Debiopharm Diagnostics led this investment round together with Emerillon Capital and will become the largest shareholder in GenePOC.

Prof. Michel G. Bergeron, Director and Founder of the Infectious Disease Research Center at Université Laval and Founder of GenePOC, with his research group, conceived this simple microfluidic real-time PCR device that is easy for almost anyone to operate whether at bedside, in the emergency room, in physician offices, in pharmacies, or even in dispensaries in the developing world. "It fulfils my dream of moving from classical Pasteur microbiology taking up to two days, to near patient <1h diagnostic results which guide appropriate management of patients on the spot," says Dr. Bergeron.

"The investment in GenePOC confirms our strong belief in the future success of Point of Care technologies. GenePOC technology has the potential to be a game changer and should be on the market in 2016," said David Deperthes, CEO of Debiopharm Diagnostics.

"With GenePOC's platform we will be able to revolutionize diagnosis of infectious diseases. It addresses the critical issues of rapidity and affordability, to give the first viable alternative to the current standard and time-consuming approach of microbial culture. We are delighted to have Debiopharm Diagnostics and Emerillon Capital as key investors," said Patrice Allibert, CEO of GenePOC.

Ludovic André, Managing Director of Emerillon Capital added: "GenePOC has the capability to offer a simple and accurate solution for Point of Care testing, and at an affordable cost which is a pre-requisite to democratize this emerging diagnostic area. Emerillon is proud to support this project driven by a world-class team in the field of molecular diagnostic."

"With the emergence of bacterial antibiotic resistance the treatment paradigm needs to be changed and the new generation of targeted antibiotics will require associated rapid low-cost diagnostics. Our Group will continue to invest on both therapeutic and diagnostic sides to tackle this important issue," stated Thierry Mauvernay, Delegate of the Board, Debiopharm Group(TM).

About Debiopharm Diagnostics SA

Debiopharm Diagnostics' mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. Since 2008, Debiopharm Diagnostics has invested over USD 85 million and led 9 out of the 13 last investment rounds in its portfolio companies.

For more information, please visit: http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

About GenePOC

Located in Québec City, Canada, GenePOC Inc. is a privately owned company that develops cost-effective and rapid molecular devices to detect genes at Point-of-Care. GenePOC has developed a simple and integrated portable instrument for the prevention and early detection of infectious diseases based on a unique centripetal technology platform. For more: http://www.genepoc-diagnostics.com/Home.shtml

About Emerillon Capital

Launched in Montreal in June 2013, Emerillon Capital is a $100M venture capital fund empowered by a strong transatlantic partnership between Groupe Crédit Mutuel - CIC and Mouvement Desjardins. Emerillon Capital is dedicated to supporting and developing technology companies in Canada and the northeastern USA. For more: emerilloncapital.com/en/index.html [http://emerilloncapital.com/en/index.html]

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator 
christelle.tur@debiopharm.com
Tel: +41-(0)21-321-01-11

Additional Media Contacts
In London
Maitland
Brian Hudspith 
bhudspith@maitland.co.uk
Tel: +44-(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive 
martina.schwarzkopf@russopartnersllc.com
Tel: +1-212-845-4292

GenePOC Contact
Patrice Allibert
CEO 
patrice.allibert@genepooc.ca
Tel: +1-418-650-3535

Emerillon Contact
Claude Kellenny 
Claude.kellenny@emerilloncapital.com
Tel : +1-514-281-2282

Plus de actualités: Debiopharm International SA
Plus de actualités: Debiopharm International SA
  • 12.01.2015 – 08:32

    Debiopharm Group(TM) Regains Full Rights to Alisporivir Program

    Lausanne, Switzerland (ots/PRNewswire) - - Novartis returns Alisporivir (DEB025) to Debiopharm Group(TM) including all rights for HCV and other indications - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that it has updated its arrangement with Novartis to regain full rights to Alisporivir (DEB025) currently completing two Phase 2 studies of interferon-free treatment in ...

  • 08.01.2015 – 09:01

    FDA Grants Fast Track Designation to Debiopharm Group's Antibiotic Debio 1450

    Lausanne, Switzerland (ots/PRNewswire) - - Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received Fast Track designation for ABSSSI (acute bacterial skin and skin structure infections) - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) ...

  • 02.12.2013 – 12:23

    BPA Solutions get Investment funds to accelerate rapid growth and global expansion

    Yverdon, Switzerland (ots) - BPA Solutions SA (BPA), headquartered at Swiss Technopole Yverdon, Switzerland, today announced it has raised development funds from Debiopharm Investment. BPA is a global leading provider of innovative business software solutions based on Microsoft (MS) SharePoint technologies with 800+ customers and 50+ partners worldwide. Profitable ...